Related Experiment Video
Updated: Jun 9, 2025
A RANKL-based Osteoclast Culture Assay of Mouse Bone Marrow to Investigate the Role of mTORC1 in Osteoclast Formation
Published on: March 15, 2018
IMPC-based screening revealed that ROBO1 can regulate osteoporosis by inhibiting osteogenic differentiation
Xiangzheng Zhang1, Yike Wang2, Miao Zheng1
1The Osteoporosis Clinical Center, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Introduction:
The utilization of denosumab in treating osteoporosis highlights promising prospects for osteoporosis intervention guided by gene targets. While omics-based research into osteoporosis pathogenesis yields a plethora of potential gene targets for clinical transformation, identifying effective gene targets has posed challenges.
Methods:
We first queried the omics data of osteoporosis clinical samples on PubMed, used International Mouse Phenotyping Consortium (IMPC) to screen differentially expressed genes, and conducted preliminary functional verification of candidate genes in human Saos2 cells through osteogenic differentiation and mineralization experiments. We then selected the candidate genes with the most significant effects on osteogenic differentiation and further verified the osteogenic differentiation and mineralization functions in mouse 3T3-E1 and bone marrow mesenchymal stem cells (BMSC). Finally, we used RNA-seq to explore the regulation of osteogenesis by the target gene.
Results:
We identified PPP2R2A, RRBP1, HSPB6, SLC22A15, ADAMTS4, ATP8B1, CTNNB1, ROBO1, and EFR3B, which may contribute to osteoporosis. ROBO1 was the most significant regulator of osteogenesis in both human and mouse osteoblast. The inhibitory effect of Robo1 knockdown on osteogenic differentiation may be related to the activation of inflammatory signaling pathways.
Conclusion:
Our study provides several novel molecular mechanisms involved in the pathogenesis of osteoporosis. ROBO1 is a potential target for osteoporosis intervention.
Insights
Researchers identified novel gene targets for osteoporosis intervention, with ROBO1 showing significant potential. This discovery advances understanding of osteoporosis pathogenesis and offers new therapeutic avenues.
Area of Science:
- Molecular Biology
- Genetics
- Biochemistry
Background:
- Osteoporosis treatment faces challenges in identifying effective gene targets despite advances in omics research.
- Denosumab shows promise for osteoporosis intervention, highlighting the need for gene-target strategies.
Purpose of the Study:
- To identify novel gene targets for osteoporosis intervention.
- To investigate the role of specific genes in osteogenic differentiation and bone formation.
Main Methods:
- Queried omics data from osteoporosis samples and used the International Mouse Phenotyping Consortium (IMPC) to screen differentially expressed genes.
- Conducted in vitro experiments on human Saos2 cells, mouse 3T3-E1 cells, and bone marrow mesenchymal stem cells (BMSCs) to assess osteogenic differentiation and mineralization.
- Utilized RNA sequencing (RNA-seq) to explore the regulatory mechanisms of target genes in osteogenesis.
Main Results:
- Identified nine candidate genes (PPP2R2A, RRBP1, HSPB6, SLC22A15, ADAMTS4, ATP8B1, CTNNB1, ROBO1, EFR3B) potentially involved in osteoporosis.
- ROBO1 emerged as the most significant regulator of osteogenesis in both human and mouse osteoblasts.
- Robo1 knockdown inhibited osteogenic differentiation, potentially via activation of inflammatory signaling pathways.
Conclusions:
- The study elucidates novel molecular mechanisms underlying osteoporosis pathogenesis.
- ROBO1 represents a promising molecular target for future osteoporosis interventions.
